These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
444 related articles for article (PubMed ID: 29746229)
21. Randomized phase II study of second-line chemotherapy with the best available 5-fluorouracil regimen versus weekly administration of paclitaxel in far advanced gastric cancer with severe peritoneal metastases refractory to 5-fluorouracil-containing regimens (JCOG0407). Nishina T; Boku N; Gotoh M; Shimada Y; Hamamoto Y; Yasui H; Yamaguchi K; Kawai H; Nakayama N; Amagai K; Mizusawa J; Nakamura K; Shirao K; Ohtsu A; Gastric Cancer; 2016 Jul; 19(3):902-10. PubMed ID: 26386560 [TBL] [Abstract][Full Text] [Related]
22. [Treatment for advanced gastric cancer with positive lavage cytology-systemic versus intraperitoneal chemotherapy]. Iwasaki Y; Ohashi M; Nunobe S; Iwanaga T; Iwagami S; Takahashi K; Yamaguchi T; Matsumoto H; Nakano D Gan To Kagaku Ryoho; 2008 Nov; 35(12):2009-11. PubMed ID: 19106506 [TBL] [Abstract][Full Text] [Related]
23. Phase I study of combination chemotherapy consisting of paclitaxel, cisplatin, and S-1 in patients with unresectable gastric cancer (KOGC-02). Takahashi T; Saikawa Y; Fukuda K; Funakoshi S; Kawakubo H; Takeuchi H; Takaishi H; Kitagawa Y Anticancer Res; 2012 Dec; 32(12):5401-6. PubMed ID: 23225443 [TBL] [Abstract][Full Text] [Related]
24. Docetaxel, cisplatin and S-1 (DCS) combination chemotherapy for gastric cancer patients with peritoneal metastasis: a retrospective study. Ohnuma H; Sato Y; Hirakawa M; Kikuchi S; Miyanishi K; Sagawa T; Takahashi Y; Nobuoka T; Okamoto K; Miyamoto H; Takemasa I; Takayama T; Kato J Cancer Chemother Pharmacol; 2018 Mar; 81(3):539-548. PubMed ID: 29383482 [TBL] [Abstract][Full Text] [Related]
25. A comparison of multimodality treatment: two or four courses of paclitaxel plus cisplatin or S-1 plus cisplatin followed by surgery for locally advanced gastric cancer, a randomized Phase II trial (COMPASS). Yoshikawa T; Tsuburaya A; Morita S; Kodera Y; Ito S; Cho H; Miyashita Y; Sakamoto J Jpn J Clin Oncol; 2010 Apr; 40(4):369-72. PubMed ID: 20299499 [TBL] [Abstract][Full Text] [Related]
26. Sequential paclitaxel followed by tegafur and uracil (UFT) or S-1 versus UFT or S-1 monotherapy as adjuvant chemotherapy for T4a/b gastric cancer (SAMIT): a phase 3 factorial randomised controlled trial. Tsuburaya A; Yoshida K; Kobayashi M; Yoshino S; Takahashi M; Takiguchi N; Tanabe K; Takahashi N; Imamura H; Tatsumoto N; Hara A; Nishikawa K; Fukushima R; Nozaki I; Kojima H; Miyashita Y; Oba K; Buyse M; Morita S; Sakamoto J Lancet Oncol; 2014 Jul; 15(8):886-93. PubMed ID: 24954805 [TBL] [Abstract][Full Text] [Related]
27. [A phase II prospective randomized controlled trial of weekly paclitaxel combined with S-1 or fluorouracil for advanced gastric carcinoma]. Huang DZ; Xiong JP; Xu N; Yan Z; Zhuang ZX; Yu Z; Wan HP; Zhang Y; Deng T; Zheng RS; Guo ZQ; Hu CH; Wang ML; Yu ZH; Yao Y; Meng JC; Ba Y Zhonghua Zhong Liu Za Zhi; 2012 Nov; 34(11):865-8. PubMed ID: 23291139 [TBL] [Abstract][Full Text] [Related]
28. Randomized phase II trial of S-1 plus irinotecan versus S-1 plus paclitaxel as first-line treatment for advanced gastric cancer (OGSG0402). Sugimoto N; Fujitani K; Imamura H; Uedo N; Iijima S; Imano M; Shimokawa T; Kurokawa Y; Furukawa H; Goto M Anticancer Res; 2014 Feb; 34(2):851-7. PubMed ID: 24511022 [TBL] [Abstract][Full Text] [Related]
29. S-1 Based Doublet as an Adjuvant Chemotherapy for Curatively Resected Stage III Gastric Cancer: Results from the Randomized Phase III POST Trial. Lee CK; Jung M; Kim HS; Jung I; Shin DB; Kang SY; Zang DY; Kim KH; Lee MH; Kim BS; Lee KH; Cheong JH; Hyung WJ; Noh SH; Chung HC; Rha SY Cancer Res Treat; 2019 Jan; 51(1):1-11. PubMed ID: 29397659 [TBL] [Abstract][Full Text] [Related]
30. A phase I study of triplet combination chemotherapy of paclitaxel, cisplatin and S-1 in patients with advanced gastric cancer. Kimura Y; Yano H; Imamura H; Fujitani K; Imano M; Tokunaga Y; Matsuoka M; Kurokawa Y; Shimokawa T; Takiuchi H; Tsujinaka T; Furukawa H Jpn J Clin Oncol; 2013 Feb; 43(2):125-31. PubMed ID: 23225911 [TBL] [Abstract][Full Text] [Related]
31. A phase I study of S-1 in combination with nab-paclitaxel in patients with unresectable or recurrent gastric cancer. Nakayama N; Ishido K; Chin K; Nishimura K; Azuma M; Matsusaka S; Inokuchi Y; Tanabe S; Kumekawa Y; Koizumi W Gastric Cancer; 2017 Mar; 20(2):350-357. PubMed ID: 27189323 [TBL] [Abstract][Full Text] [Related]
32. Phase I open-label trial of intraperitoneal paclitaxel in combination with intravenous cisplatin and oral capecitabine in patients with advanced gastric cancer and peritoneal metastases (IPGP study): study protocol. Vatandoust S; Bright T; Roy AC; Watson D; Gan S; Bull J; Abbas MN; Karapetis CS BMJ Open; 2019 May; 9(5):e026732. PubMed ID: 31061042 [TBL] [Abstract][Full Text] [Related]
33. Surgery after intraperitoneal and systemic chemotherapy for gastric cancer with peritoneal metastasis or positive peritoneal cytology findings. Ishigami H; Yamaguchi H; Yamashita H; Asakage M; Kitayama J Gastric Cancer; 2017 Mar; 20(Suppl 1):128-134. PubMed ID: 28028665 [TBL] [Abstract][Full Text] [Related]
34. A phase II study of biweekly S-1 and paclitaxel (SPA) as first-line chemotherapy in patients with metastatic or advanced gastric cancer. Jiang H; Qian J; Zhao P; Zhang X; Zheng Y; Mao C; Zheng Y; Chen L; Wang Y; Mou H; Fang W; Teng L; Xu N Cancer Chemother Pharmacol; 2015 Jul; 76(1):197-203. PubMed ID: 26013324 [TBL] [Abstract][Full Text] [Related]
35. [Repeated occlusion of the intraperitoneal access port for intraperitoneal chemotherapy in a patient with gastric cancer with peritoneal dissemination]. Sasaki K; Fujiwara Y; Kishi K; Motoori M; Sugimura K; Miyoshi N; Akita H; Gotoh K; Takahashi H; Marubashi S; Noura S; Ohue M; Yano M; Sakon M; Ishigami H; Kitayama J Gan To Kagaku Ryoho; 2013 Nov; 40(12):2319-21. PubMed ID: 24394098 [TBL] [Abstract][Full Text] [Related]
36. Addition of sintilimab to nanoparticle albumin-bound paclitaxel and S-1 as adjuvant therapy in stage IIIC gastric cancer. Mei Y; Shi M; Zhu Z; Yuan H; Yan C; Li C; Feng T; Yan M; Zhang J; Zhu Z Future Oncol; 2022 Jan; 18(2):139-148. PubMed ID: 34877867 [TBL] [Abstract][Full Text] [Related]
38. Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study. Boku N; Yamamoto S; Fukuda H; Shirao K; Doi T; Sawaki A; Koizumi W; Saito H; Yamaguchi K; Takiuchi H; Nasu J; Ohtsu A; Lancet Oncol; 2009 Nov; 10(11):1063-9. PubMed ID: 19818685 [TBL] [Abstract][Full Text] [Related]
39. Feasibility of weekly intraperitoneal versus intravenous paclitaxel therapy delivered from the day of radical surgery for gastric cancer: a preliminary safety analysis of the INPACT study, a randomized controlled trial. Kodera Y; Takahashi N; Yoshikawa T; Takiguchi N; Fujitani K; Ito Y; Miyamoto K; Takayama O; Imano M; Kobayashi D; Miyashita Y; Morita S; Sakamoto J Gastric Cancer; 2017 Jan; 20(1):190-199. PubMed ID: 26879545 [TBL] [Abstract][Full Text] [Related]
40. A Phase 2 Study of Induction Chemotherapy Using Docetaxel, Cisplatin, and S-1 for Gastric Cancer with Peritoneal Metastasis (KUGC06). Okabe H; Hata H; Hosogi H; Ueda S; Ota S; Kinjo Y; Hoshino N; Hisamori S; Tsunoda S; Obama K; Sakai Y; Ann Surg Oncol; 2019 Jun; 26(6):1779-1786. PubMed ID: 30767179 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]